3416-26-0

Basic information

• Product Name: LIDOFLAZINE, 98.5%
• Synonyms: 1-(4,4-bis(4-fluorofenil)butil)-4-((2,6-dimetilanilinocarbonil)metil)piperaz;1-piperazineacetamide,4-(4,4-bis(4-fluorophenyl)butyl)-n-(2,6-dimethylphenyl;4-(4,4-bis(p-fluorophenyl)butyl)-1-piperazineaceto-2’,6’-xylidide;6’-xylidide,4-(4,4-bis(p-fluorophenyl)butyl)-1-piperazineaceto-2;clinium;corflazine;klinium;lidoflazin
• CAS NO: 3416-26-0
• Molecular Formula: C₃₀H₃₅F₂N₃O
• Molecular Weight: 491.622
• EINECS: 222-312-8
• Mol File: 3416-26-0.mol
• Article Data: 1

Chemical Properties

• Melting Point: 159-161°
• Boiling Point: 632.6°Cat760mmHg
• Flash Point: 336.4°C
• Appearance: white/
• Density: 1.1322 (estimate)
• Vapor Pressure: 6.57E-16mmHg at 25°C
• Refractive Index: 1.581
• Storage Temp.: 2-8°C
• Solubility: DMSO: ≥10mg/mL
• PKA: 14.62±0.70(Predicted)
• CAS DataBase Reference: LIDOFLAZINE, 98.5%(CAS DataBase Reference)
• NIST Chemistry Reference: LIDOFLAZINE, 98.5%(3416-26-0)
• EPA Substance Registry System: LIDOFLAZINE, 98.5%(3416-26-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Safety Statements: 36
• WGK Germany: 3
• RTECS: TK7910000
• Hazardous Substances Data: 3416-26-0(Hazardous Substances Data)

Usage

Chemical Properties

WHITE TO ALMOST WHITE POWDER

Originator

Clinium,Janssen,W. Germany,1969

Uses

Different sources of media describe the Uses of 3416-26-0 differently. You can refer to the following data:
1. Coronary vasodilatator;Ca++ channel activator
2. Lidoflazine is a L-type Ca2+ channel antagonist.Also, it is derived from 1,1''-(4-Chlorobutylidene)bis(4-fluorobenzene) (C364775), which is a derivative of Zerumbone with potential anti-tumor effects towards HeLa cancer cells.

Manufacturing Process

A mixture of 6.6 parts 1-[4,4-di-(4-fluoro-phenyl)butyl]-piperazine, 4.33 parts N-(2-chloro-acetyl)-2,6-dimethyl-aniline, 3.2 parts sodium carbonate, a few crystals of potassium iodide in 200 parts 4-methyl-2-pentanone is stirred and refluxed for 70 hours. After cooling there are added 70 parts water. The organic layer is separated, dried over potassium carbonate, filtered and evaporated. The oily residue is dissolved in 80 parts diisopropylether and the solution is filtered hot. After cooling the filtrate at 0°C. the formed solid is filtered off and recystallired from 80 parts ether, yielding 1-[4,4-di-(4-fluorophenyl)butyl]-4-[(2,6-dimethylanilino-carbonyl)-methyl]-piperazine; MP 159°C to 161°C.

Brand name

Angex (Janssen); Clinium (Ortho-McNeil).

Therapeutic Function

Coronary vasodilator

InChI:InChI=1/C30H35F2N3O/c1-22-5-3-6-23(2)30(22)33-29(36)21-35-19-17-34(18-20-35)16-4-7-28(24-8-12-26(31)13-9-24)25-10-14-27(32)15-11-25/h3,5-6,8-15,28H,4,7,16-21H2,1-2H3,(H,33,36)

Relevant articles and documents

METHODS FOR TREATING CHRONIC FATIGUE SYNDROME AND MYALGIC ENCEPHALOMYELITIS

In one aspect the invention relates to a method of treatment selected from the group consisting of: (a) treating a symptom such as pain in a subject identified or diagnosed as having Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS); (b) treating a symptom such as pain in a subject having dysfunctional TRPM3 ion channel activity; (c) restoring NK cell function in a subject having dysfunctional TRPM3 ion channel activity; and (d) restoring calcium homeostasis in a subject having dysfunctional TRPM3 ion channel activity. The method comprises the step of administering to the subject a therapeutically effective amount of at least one therapeutic compound selected from the group consisting of: (i) an opioid receptor antagonist; (ii) an opioid antagonist; and (iii) a therapeutic compound that restores TRPM3 ion channel activity. In some embodiments the therapeutic compound is naltrexone hydrochloride.